Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Horizon Therapeutics Ireland Dac manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 5 pending office actions. These actions are handled by 5 distinct examiners, meaning each pending action is being reviewed by a different examiner. Prosecution work is spread across 5 distinct art units, reflecting the technical breadth of the company's biotechnology innovations.
ALLEN, MARIANNE P is the busiest examiner, currently overseeing 1 busiest examiner pending office action. This matching number between 5 pending office actions, 5 distinct examiners, and 5 art units indicates a highly decentralized prosecution effort for the company. The involvement of 5 distinct art units further underscores the breadth of the company's current examination landscape. ALLEN, MARIANNE P handles 1 busiest examiner pending office action, which is the same number of actions assigned to every other examiner in this portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| Double-patenting + other | 2 (40%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALLEN, MARIANNE P | 1 | 60.1% | +18.4% |
| FERGUSON, JALISA HOLMES | 1 | 62.2% | +41.2% |
| GIBBS, TERRA C | 1 | 63.7% | +10.4% |
| GREEN, MALIA NICOLE | 1 | — | — |
| DONOGHUE, BRITTNEY ERIN | 1 | 58.7% | +47.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19639842 | METHODS FOR THE TREATMENT OF THYROID EYE DISEASE | ALLEN, MARIANNE P | — |
| 18793698 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | FERGUSON, JALISA HOLMES | — |
| 18572698 | COMPOSITIONS AND METHODS OF MODULATING XANTHINE DEHYDROGENASE | GIBBS, TERRA C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19639842 | METHODS FOR THE TREATMENT OF THYROID EYE DISEASE | ALLEN, MARIANNE P | — |
| 18793698 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | FERGUSON, JALISA HOLMES | — |
| 18572698 | COMPOSITIONS AND METHODS OF MODULATING XANTHINE DEHYDROGENASE | GIBBS, TERRA C | — |
| 18548484 | METHODS FOR THE TREATMENT OF THYROID EYE DISEASE | DONOGHUE, BRITTNEY ERIN | — |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| 1626 | 1 |
| 1635 | 1 |
| 1643 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19639842 | METHODS FOR THE TREATMENT OF THYROID EYE DISEASE | ALLEN, MARIANNE P | 1647 | §102§103 | Final Rejection | — | Pending | Apr 06, 2026 |
| 18793698 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | FERGUSON, JALISA HOLMES | 1626 | §102§112 | Non-Final OA | — | Pending | Aug 02, 2024 |
| 18572698 | COMPOSITIONS AND METHODS OF MODULATING XANTHINE DEHYDROGENASE | GIBBS, TERRA C | 1635 | §101§102§103§112 | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18477140 | METHODS FOR TREATING INACTIVE THYROID EYE DISEASE | GREEN, MALIA NICOLE | 1643 | §102§112DP | Non-Final OA | — | Pending | Sep 28, 2023 |
| 18548484 | METHODS FOR THE TREATMENT OF THYROID EYE DISEASE | DONOGHUE, BRITTNEY ERIN | 1675 | §103§112DP | Non-Final OA | — | Pending | Aug 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHorizon Therapeutics Ireland Dac has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Marianne P Allen has the most, with 1 of Horizon Therapeutics Ireland Dac's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
